LEXINGTON, Mass., March 4, 2016 /PRNewswire/ -- Pulmatrix, Inc., (NASDAQ: PULM) will present a business update at the Cowen and Company 36th Annual Health Care Conference on Wednesday, March 9th at 11:20 am EST (8:20 am PST). A live webcast of the presentation may be accessed in the investor relations section of the Company's website at www.pulmatrix.com. A replay of the presentation will be available on the Company's website for 90 days following the presentation.
About Pulmatrix
Pulmatrix is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary disease using its patented iSPERSE™ technology. The Company's proprietary product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with cystic fibrosis (CF). In addition, Pulmatrix is pursuing opportunities in major pulmonary diseases through collaborations, including PUR0200, a branded generic in clinical development for chronic obstructive pulmonary disease (COPD). Pulmatrix's product candidates are based on iSPERSE™, its proprietary dry powder delivery platform, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes.
Logo - http://photos.prnewswire.com/prnh/20150616/223308LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/pulmatrix-to-present-at-2016-cowen-and-company-36th-annual-healthcare-conference-300230905.html
SOURCE Pulmatrix, Inc.
